 All these alterations can produce endothelial dysfunction which is present in SLE patients. Pioglitazone is a PPAR peroxisome proliferator activated receptor gamma agonist that can potentially improve insulin resistance, with a positive effect on the lipid profile lowering of triglycerides, and a discrete increase in HDL-C and improve endothelial function. 